BCR/ABL Major reflex to ABL Kinase Mutation
Alternative name:
BCR/ABL p210 (major) reflex to ABL Kinase Muation
Methodology
Molecular
Test Description and clinical significance
Genes
BCR/ABL1 (t(9;22) Major (p210) breakpoints & ABL Kinase gene
Disease:
Chronic myeloid leukemia (CML), B-cell lymphoblastic leukemia/lymphoma (B-ALL), and acute myeloid leukemia (AML).
A polymerase chain reaction that is recommended for identification of BCR-ABL1 fusion genes is used for diagnosis and ongoing therapeutic monitoring for CML. This test acess the gene mutations that may interfere with the effectiveness of tyrosine kinase inhibitor (TKI) therapy and to determine management strategy when the BCR/ABL major mutation is negative.
Specimen Requirements
Collection:
3ml EDTA, citrate (ACD) or Heparinized whole blood or bone marrow aspirates are transported at room temperature, received with 96 hr, refrigerated are stable for a week from the date of collection, Extracted RNA; a minimum volume of 20 ?l at 100ng/?l
Stability:
96hours/4 to 7 days refrigerated
Unacceptable Conditions:
Clotted peripheral blood or bone marrow. Peripheral blood or bone marrow older than a week. Leukophoresis products. Improperly labeled specimens. Improperly stored RNA.
Storage & Transport
Blood or bone marrow specimens should be kept at room temperature and preferably received within 96 hrs of drawing, Previously extracted RNA is acceptable if stored at appropriate temperature short term at -20oC (up to two weeks) or long term at -80oC and should be transported on dry ice.
CPT(s)
81206, 81170
New York Approved
NO
TAT
10 Days
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
